Lecozotan clinical trials
Includes 2 studies of Lecozotan hydrochloride.
How each study uses lecozotan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2007 (4)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Wyeth is now a wholly owned subsidiary of Pfizer (7) · Pfizer (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses lecozotan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)CompletedPhase 2Wyeth is now a wholly owned subsidiary of PfizerNCT00151398Written as lecozotan SR
- Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's DiseaseCompletedPhase 2/3PfizerNCT00277810Written as lecozotan SR (SRA-333)
- Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)CompletedPhase 2Wyeth is now a wholly owned subsidiary of PfizerNCT00151333Written as SRA-333
- Study Evaluating Potential Pharmacokinetic (PK) Interaction Between Lecozotan and DigoxinCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00563732Written as Lecozotan
- Study Evaluating the Effect of Lecozotan SR on the QTc IntervalCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00499642Written as Lecozotan SR
- Study Evaluating a Combined Administration of Lecozotan SR and Citalopram in Young Healthy SubjectsCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00538889Written as Lecozotan SR
- Study Comparing Lecozotan SR Two 5-mg Tablets Vs. Lecozotan SR One 10-mg Tablet in Healthy SubjectsCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00494962Written as lecozotan SR
- Study Evaluating the Safety of Lecozotan SR in Healthy Young and Elderly SubjectsCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00366483Written as Lecozotan SR
Codes
What other systems call lecozotan · ClinicalTrials.gg INT004784
- MeSH (NLM) C500836lecozotanOne source NLM
- UNII (FDA) 48854OTZ5ELECOZOTANConfirmed FDA, NLM, Wikidata
- Wikidata Q27259118lecozotanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C74394LecozotanOne source FDA
- DrugBank DB12540One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C500836 | lecozotan | One source NLM |
| UNII (FDA) | 48854OTZ5E | LECOZOTAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27259118 | lecozotan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C74394 | Lecozotan | One source FDA |
| DrugBank | DB12540 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.